Price Disclosure

Page last updated: 27 July 2020

Outcomes from Price Disclosure

Indicative Prices - Disclosure Cycles

Indicative price disclosure-related price changes are being made available in advance of the effective date to assist companies and other stakeholders. They will come into effect under the National Health Act 1953 and the National Health (Pharmaceutical Benefits) Regulations 2017 and have already been announced publicly - see 'Outcomes from Price Disclosure (SPD)'.

These prices are indicative only and may change if there are changes in prices or listings before the Reduction Day (e.g., lower price / pricing quantity changes).

Indicative prices are published for F2 combination drugs that are taking a direct price disclosure reduction.

Indicative prices are not published for any medicines that are:

  • not taking a price disclosure reduction in the respective cycle;
  • new brands after the date of publication;
  • brands with other price changes on the reduction day;
  • combination drugs taking flow-on price disclosure reductions; or
  • F2 combination drugs taking flow-on price disclosure reductions.

 Those other prices will be available publicly on the Effective Day.

Confirmation of New Prices – Disclosure Cycles

The spreadsheets below set out price disclosure related price changes effective on the reduction day. This includes all the levels of PBS prices previously published under the Indicative Prices heading (above).

These price disclosure related changes are being made available in advance of the effective date to assist companies.  They come into effect under the National Health Act 1953 and have already been announced publicly (refer to Outcomes from Price Disclosure section above).

Brand Price Reductions and Savings to Patients – Disclosure Cycles

The spreadsheets below set out brand level price reductions and potential individual savings to non-concessional patients effective on the reduction day mentioned.

This information is made available to assist patients with understanding how much they may save on their prescription medication as a result of the latest round of price disclosure price reductions.

Reference documents

Primary Sources

Explanatory Materials

Archived Material